Cardiovascular risk factor control among diabetic patients attending community-based diabetic care clinics in Italy

Diabetes Research and Clinical Practice

Volumn 75, Issue 2, 2007, Pages 176-183

  Colivicchi, Furio ^a   Uguccioni, Massimo ^b   Ragonese, Mauro ^c   Nardozi, Claudio ^b   Angotti, Stefania ^c   Principe, Francesco ^c   Pinto, Sandro Lo ^c   Santini, Massimo ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

^b CTO Hospital ASL Roma C   (Italy)

^c Neurol RH S Giovanni Battista   (Italy)

Author keywords

Cardiovascular risk factors; Diabetes mellitus; Hypertension; Quality of care

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMMUNITY CARE; DIABETES EDUCATION; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEALTH CARE QUALITY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; ITALY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RISK REDUCTION; URBAN AREA;

AGED; BODY SIZE; CARDIOVASCULAR DISEASES; COMMUNITY HEALTH SERVICES; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERTENSION; ITALY; MALE; MIDDLE AGED; OBESITY; PATIENT SELECTION; PREVALENCE; REGRESSION ANALYSIS; RISK FACTORS;

EID: 33845446499     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.05.013     Document Type: Article

References (27)

1. Grundy S.M., Benjamin I.J., Burke G.L., Chait A., Eckel R.H., Howard B.V., et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100 (1999) 1134-1146
2. Rodriguez B.L., Curb J.D., Burchfiel C.M., Huang B., Sharp D.S., Lu G.Y., et al. Impaired glucose tolerance, diabetes, and cardiovascular disease risk factor profiles in the elderly: the Honolulu Heart Program. Diab. Care 19 (1996) 587-590
3. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
4. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial: the HOT Study Group. Lancet 351 (1998) 1755-1762
5. Adler A.I., Stratton I.M., Neil H.A., Yudkin J.S., Matthews D.R., Cull C.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321 (2000) 412-419
6. Haffner S.M., Alexander C.M., Cook T.J., Boccuzzi S.J., Musliner T.A., Pedersen T.R., et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch. Intern. Med. 159 (1999) 2661-2667
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
8. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
9. De Backer G., Ambrosioni E., Borch-Jonsen K., Brontos C., Cifkova R., Dallongeville J., et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur. J. Cardiovasc. Prev. Rehabil. 10 Suppl 1 (2003) S1-S78
10. Agenzia di Sanità Pubblica della Regione Lazio. La qualità dell'assistenza ai diabetici nelle regioni italiane. Lo studio QuADRI nel Lazio. Roma, 2005.
11. The Italian cardiovascular epidemiological observatory, It. Heart J. 5 (Suppl 1) (2004) 49S-92S.
12. Rose G.A., Blackburn H., Gillum R.F., and Prineas R.J. Cardiovascular Survey Methods (1982), World Health Organization, Geneva
13. Haffner S.M. Coronary heart disease in patients with diabetes. N. Engl. J. Med. 342 (2000) 1040-1042
14. Gu K., Cowie C.C., and Harris M.I. Mortality in adults with and without diabetes in a national cohort of the US population. Diab. Care 21 (1998) 1138-1145
15. Fischer M. Diabetes: can we stop the time bomb?. Heart 89 Suppl. II (2003) II28-II30
16. American Diabetes Association. Smoking and diabetes. Diab. Care 24 Suppl. 1 (2001) S64-S65
17. McFarlane S.I., Jacober S.J., Winer N., Kaur J., Castro J.P., Wui M.A., et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diab. Care 25 (2002) 718-723
18. Comaschi M., Costelli C., Cucinotta D., Malini P., Manzato E., and Nicolucci A. Cardiovascular risk factors and metabolic control in type 2 diabetic subjects attending outpatient clinics in Italy: The SFIDA (survey of risk factors in Italian diabetic subjects by AMD) study. Nutr. Metab. Cardiovasc. Dis. 15 (2005) 204-211
19. McFarlane S.I., Castro J.P., Kaur J., Shin J.J., Kelling Jr. D., Farag A., et al. Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J. Clin. Hypertens. 7 (2005) 73-80
20. Nilsson P.M., Theobald H., Journath G., and Fritz T. Gender differences in risk factor control and treatment profile in diabetes: a study in 229 Swedish primary health care. Scand. J. Prim. Health Care 22 (2004) 27-31
21. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355 (2000) 253-259
22. Degli Esposti E., Di Martino M., Sturani A., Russo P., Dradi C., Falcinelli S., et al. Risk factors for uncontrolled hypertension in Italy. J. Hum. Hypertens. 18 (2004) 207-213
23. Mazzaglia G., Mantovani L.G., Sturkenboom M.C., Filippi A., Trifiro G., Cricelli C., et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J. Hypertens. 23 (2005) 2093-2100
24. The DAI study group. The DAI prospective study on macrovascular complications in patients with type 2 diabetes. Characteristics of the study population. Ann. Ist Sup. San. 37 (2001) 289-296
25. Maggini M., Spila Alegiani S., and Raschetti R. Complicanze macroangiopatiche nei pazienti diabetici di tipo 2 afferenti ai servizi di diabetologia italiani. Ann. Ist Sup. San. 39 (2003) 165-171
26. Colwell J.A. Aspirin therapy in diabetes. Diab. Care 26 Suppl 1 (2003) S87-S88
27. Rolka D.B., Fagot-Campagna A., and Narayan K.M. Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diab. Care 24 (2001) 197-201